Sep 7, 2022Anavex Life Sciences to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
Aug 9, 2022Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Aug 3, 2022Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022
Aug 2, 2022Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Jul 31, 2022Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
May 19, 2022Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
May 3, 2022Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tues. May 10, 2022
Apr 27, 2022Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Mar 15, 2022Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Feb 10, 2022Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Jan 10, 2022Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
Sep 26, 2021Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access